Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase year-on-year [1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, representing a 5.95% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a year-on-year growth of 19.17% [1] - Basic earnings per share were reported at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [1] - There is a further segmentation of product lines through detailed management by sales divisions, which aims to improve the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [1] - The company is concentrating on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]

Core Viewpoint - Spring Medical (01858) reported a strong performance for the fiscal year 2025, with total revenue of approximately 1.044 billion yuan, representing a year-on-year growth of 29.52%, and a net profit attributable to shareholders of approximately 272 million yuan, reflecting a significant increase of 117.72% [1] Revenue Growth - The growth in revenue is primarily attributed to the normalization of national procurement for orthopedic consumables, which has led to a steady increase in product sales and an expansion of domestic business scale and market share [1] - The company has successfully leveraged its comprehensive channel coverage and diverse product portfolio to enhance profitability [1] International Expansion - Spring Medical is advancing its international strategy, achieving continuous expansion and breakthroughs in international markets, supported by products that meet international advanced standards in technology and quality [1] - The steady increase in overseas revenue has been a crucial contributor to the overall performance growth of the company [1] Operational Efficiency - The company is focusing on refined operational management and optimizing operational efficiency, which has led to significant improvements in overall operational efficiency and profitability [1] - Through large-scale production, the company has further strengthened its economies of scale, contributing to enhanced operational performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...

Group 1 - The A-share medical sector showed positive performance on February 27, with the largest medical ETF (512170) rising by 1.14% and successfully recovering the annual line, with a transaction volume of 384 million CNY [1][9] - The ETF experienced continuous premium trading, indicating a positive buying sentiment, with over 190 million CNY net subscriptions in the previous three days [1][9] - The leading stock, Huatai Medical, surged by 8.24%, with its performance report indicating over 20% year-on-year growth in revenue and net profit for 2025 [1][11] Group 2 - The Hong Kong medical sector rebounded after several days of decline, with the Hong Kong medical ETF (159137) recovering from a historical low, ending a six-day losing streak [3][11] - CXO companies, particularly those under WuXi AppTec, showed strong performance, with shares rising by 8.23% for WuXi AppTec, 5% for WuXi Biologics, and 3.21% for WuXi AppTec [3][11] - Citic Securities remains optimistic about the growth potential and space for the CXO sector due to increasing overseas orders and a gradual recovery in domestic demand [4][12] Group 3 - In the medical device industry, Citic Securities believes that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, suggesting an allocation increase in 2026 [6][14] - Investment opportunities are expected to arise from performance recovery, international expansion, brain-computer interfaces, and AI medical applications [6][14] - The medical ETF fund size reached 27.7 billion CNY, making it the largest in the medical sector, covering various themes including brain-computer interfaces and innovative medical devices [7][14]

格隆汇2月27日丨春立医疗(01858.HK)公告， 2025年度业绩快报，公司实现营业总收入人民币10.4亿 元，较上年同期增长29.52%；实现归属于母公司所有者的净利润人民币2.72亿元，较上年同期增长 117.72%。 报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长；同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 ...

Group 1 - The company reported a revenue of 2.473 billion yuan for the fiscal year 2025, representing a year-on-year decrease of 8.33% [1] - The net profit attributable to the parent company was 251 million yuan, down 40.30% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 160 million yuan, a decrease of 57.67% year-on-year [1] Group 2 - The company's subsidiary, Shenzhen New Industry Ophthalmic New Technology Co., faced significant operational pressure due to the second phase of the national volume-based procurement for artificial lenses and intensified industry competition [2] - The total number of cataract surgeries in China in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - The increase in domestic competitors, particularly those offering significant cost advantages, has negatively impacted the sales price and volume of the imported Lenstec brand products [2] - The company anticipates a decrease in sales profit for Shenzhen New Industry in 2025 and has prudently recognized an impairment provision of approximately 140 million yuan for goodwill [2]

Core Viewpoint - Spring Medical (01858) reported a significant increase in revenue and net profit for the fiscal year 2025, driven by the normalization of national procurement for orthopedic consumables and steady international business expansion [1] Financial Performance - Total revenue for the year reached approximately 1.044 billion yuan, representing a year-on-year growth of 29.52% [1] - Net profit attributable to the parent company was about 272 million yuan, showing a remarkable year-on-year increase of 117.72% [1] - Basic earnings per share stood at 0.71 yuan [1] Business Growth Drivers - The growth in performance is primarily attributed to the steady increase in product sales due to the normalization of national procurement for orthopedic consumables [1] - The company has expanded its domestic business scale and market share, which has contributed to the steady improvement in profitability [1] - Continuous internationalization strategy has led to sustained business expansion in international markets, providing significant support for overall performance growth [1] Operational Efficiency - The company has focused on refined operational management and optimized operational efficiency [1] - Through large-scale production, the company has strengthened its economies of scale, resulting in significant improvements in overall operational efficiency and profitability [1]

Group 1 - The core point of the article highlights that Xiangsheng Medical reported a revenue of approximately 447 million yuan for the year 2025, representing a year-on-year decrease of 4.55% [1] - The net profit attributable to shareholders of the listed company is approximately 117 million yuan, which reflects a year-on-year decline of 16.99% [1] - The basic earnings per share is reported at 1.04 yuan, showing a decrease of 17.46% compared to the previous year [1] Group 2 - The article also mentions a significant shift in AI usage, with China's AI call volume surpassing that of the United States for the first time, leading to a surge in various sectors in the A-share market [1] - A well-known Wall Street analyst commented on China's computing power path, suggesting it disrupts traditional perceptions [1]

Group 1 - The core viewpoint of the article indicates that Xiangsheng Medical is set to release its 2025 annual report, with a reported net profit of 116.6 million yuan, reflecting a year-on-year decrease of 16.99% [1] Group 2 - During the reporting period, the company achieved an operating revenue of 447.35 million yuan, a decrease of 4.55% compared to the same period last year [2] - The net profit attributable to the parent company was 116.63 million yuan, down 16.99% year-on-year, while the net profit after deducting non-recurring gains and losses was 103.36 million yuan, a decline of 18.69% [2] - Basic earnings per share were reported at 1.04 yuan, a decrease of 17.46% compared to the previous year [2] - At the end of the reporting period, the company had total assets of 1.598 billion yuan, an increase of 0.11% year-on-year, while the equity attributable to the parent company decreased by 2.59% to 1.384 billion yuan [2] - The decline in net profit was primarily attributed to a decrease in operating revenue and foreign exchange losses due to fluctuations in the US dollar exchange rate [2] Group 3 - Xiangsheng Medical specializes in the research, development, manufacturing, and sales of ultrasound medical imaging equipment, providing various ultrasound medical imaging devices and professional technical development services to domestic and international medical institutions and research organizations [4] - In the last 90 days, three institutions have given buy ratings for the stock [5]

Group 1 - The core point of the article highlights that Aihuilong reported a significant decline in its financial performance for the year 2025, with operating revenue of approximately 1.809 billion yuan, a year-on-year decrease of 10.07% [1] - The net profit attributable to shareholders of the listed company was 24.019 million yuan, reflecting a substantial year-on-year decrease of 92.03% [1] - Basic earnings per share were reported at 0.04 yuan, which represents a year-on-year decline of 92.45% [1] Group 2 - The article also notes that in February, China's AI usage surpassed that of the United States for the first time, with four major models ranking among the top five globally, indicating a rapid growth in domestic computing power demand [1]